uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
Univ Complutense, CNIO, Hosp Univ Doce Octubre, Med Oncol Dept.
Univ Hosp Marburg UKGM, Div Gastroenterol & Endocrinol.
Univ Manchester, Inst Canc Sci, Christie NHS Fdn Trust, Dept Med Oncol, Manchester.
European Inst Oncol, Unit Gastrointestinal Med Oncol & Neuroendocrine.
Show others and affiliations
2017 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 105, no 3, 281-294 p.Article in journal (Refereed) Published
Abstract [en]

Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan).

Place, publisher, year, edition, pages
2017. Vol. 105, no 3, 281-294 p.
Keyword [en]
Neuroendocrine tumors, Chemotherapy, Standard of care, Dosing schedules, Toxicity, Drug interactions
National Category
Endocrinology and Diabetes Neurosciences Neurology
Identifiers
URN: urn:nbn:se:uu:diva-336664DOI: 10.1159/000473892ISI: 000411501200008PubMedID: 28380493OAI: oai:DiVA.org:uu-336664DiVA: diva2:1170820
Available from: 2018-01-04 Created: 2018-01-04 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Eriksson, Barbro

Search in DiVA

By author/editor
Eriksson, Barbro
By organisation
Endocrine Tumor Biology
In the same journal
Neuroendocrinology
Endocrinology and DiabetesNeurosciencesNeurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf